S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:KOD

Kodiak Sciences (KOD) Stock Price, News & Analysis

$5.26
-2.19 (-29.40%)
(As of 03/28/2024 ET)
Today's Range
$5.13
$6.88
50-Day Range
$3.12
$7.45
52-Week Range
$1.37
$9.80
Volume
3.50 million shs
Average Volume
1.02 million shs
Market Capitalization
$275.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

Kodiak Sciences MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.83 Rating Score
Upside/​Downside
28.3% Upside
$6.75 Price Target
Short Interest
Healthy
3.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.36mentions of Kodiak Sciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.78) to ($3.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.58 out of 5 stars

Medical Sector

90th out of 938 stocks

Biological Products, Except Diagnostic Industry

15th out of 148 stocks

KOD stock logo

About Kodiak Sciences Stock (NASDAQ:KOD)

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

KOD Stock Price History

KOD Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Kodiak Sciences Shares Fall 24% on 4Q EPS Miss
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Preview: Kodiak Sciences's Earnings
KOD Mar 2024 3.500 call
Dolphin Rescued After Getting Tangled in Crab Pot Line
Old lifeboat station to become seal rescue centre
See More Headlines
Receive KOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:KOD
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.75
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+28.3%
Consensus Rating
Reduce
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$-333,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.34 per share

Miscellaneous

Free Float
28,650,000
Market Cap
$275.99 million
Optionable
Optionable
Beta
2.17
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Victor Perlroth M.D. (Age 51)
    Co-Founder, Chairman, CEO & President
    Comp: $1.08M
  • Mr. John A. Borgeson CPAMr. John A. Borgeson CPA (Age 62)
    M.B.A., Senior VP, CFO & Secretary
    Comp: $667.52k
  • Dr. Michael S. Louie Ph.D.
    Senior VP of Digital Transformation & Chief Information Officer
  • Dr. Hong Liang (Age 52)
    Senior Vice President of Discovery Medicine
    Comp: $300.71k
  • Dr. Stephen Raillard Ph.D.
    Senior Vice President of Chemical Development & Manufacturing
  • Ms. Almas Qudrat M.Sc.
    Senior Vice President of Quality Operations
  • Dr. J. Pablo Velazquez-Martin M.D.
    Senior VP of Clinical Research & Development
  • Tracy Chien
    VP & Corporate Controller

KOD Stock Analysis - Frequently Asked Questions

Should I buy or sell Kodiak Sciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" KOD shares.
View KOD analyst ratings
or view top-rated stocks.

What is Kodiak Sciences' stock price target for 2024?

6 Wall Street research analysts have issued 12 month price targets for Kodiak Sciences' shares. Their KOD share price targets range from $2.00 to $12.00. On average, they expect the company's stock price to reach $6.75 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for KOD
or view top-rated stocks among Wall Street analysts.

How have KOD shares performed in 2024?

Kodiak Sciences' stock was trading at $3.04 on January 1st, 2024. Since then, KOD shares have increased by 73.0% and is now trading at $5.26.
View the best growth stocks for 2024 here
.

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NASDAQ:KOD) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($1.16) by $0.14.

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did Kodiak Sciences IPO?

Kodiak Sciences (KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers.

Who are Kodiak Sciences' major shareholders?

Kodiak Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (3.38%), Vanguard Group Inc. (3.13%), Vanguard Group Inc. (3.13%), Dimensional Fund Advisors LP (0.83%), Goldman Sachs Group Inc. (0.75%) and Goldman Sachs Group Inc. (0.75%). Insiders that own company stock include Bros Advisors Lp Baker, Jason Ehrlich, John A Borgeson and Victor Perlroth.
View institutional ownership trends
.

How do I buy shares of Kodiak Sciences?

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KOD) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners